Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning (RIC) regimens are increasingly used for the hematopoietic cell transplantation (HCT) of pediatric and young adult patients with nonmalignant diseases. Early experience suggests that these regimens are associated with good surviv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Marsh, Rebecca A., Rao, Marepalli B., Gefen, Aharon, Bellman, Denise, Mehta, Parinda A., Khandelwal, Pooja, Chandra, Sharat, Jodele, Sonata, Myers, Kasiani C., Grimley, Michael, Dandoy, Christopher, El-Bietar, Javier, Kumar, Ashish R., Leemhuis, Tom, Zhang, Kejian, Bleesing, Jack J., Jordan, Michael B., Filipovich, Alexandra H., Davies, Stella M.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603747/
https://ncbi.nlm.nih.gov/pubmed/25865646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.04.009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars